{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T09:55:03Z","timestamp":1771062903642,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001349","name":"MOH | National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/LCG\/0042018"],"award-info":[{"award-number":["NMRC\/LCG\/0042018"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1038\/s41433-020-01315-x","type":"journal-article","created":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T19:03:05Z","timestamp":1606330985000},"page":"2793-2801","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Extended intervals for wet AMD patients with high retreatment needs: informing the risk during COVID-19, data from real-world evidence"],"prefix":"10.1038","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7458-7081","authenticated-orcid":false,"given":"Kelvin Yi Chong","family":"Teo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vuong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Barthelmes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer J.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark C.","family":"Gillies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chui Ming Gemmy","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,25]]},"reference":[{"key":"1315_CR1","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565\u201374.","journal-title":"Lancet"},{"key":"1315_CR2","unstructured":"World Health Organisation. Coronavirus disease (COVID-2019) situation reports\u2014situation report 51. Geneva, Switzerland: World Health Organisation; 2019."},{"key":"1315_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-018-5446-1","volume":"18","author":"F Ahmed","year":"2018","unstructured":"Ahmed F, Zviedrite N, Uzicanin A. Effectiveness of workplace social distancing measures in reducing influenza transmission: a systematic review. BMC Public Health. 2018;18:518.","journal-title":"BMC Public Health"},{"key":"1315_CR4","doi-asserted-by":"publisher","first-page":"taaa020","DOI":"10.1093\/jtm\/taaa020","volume":"27","author":"A Wilder-Smith","year":"2020","unstructured":"Wilder-Smith A, Freedman DO. Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak. J Travel Med. 2020;27:taaa020. https:\/\/doi.org\/10.1093\/jtm\/taaa020.","journal-title":"J Travel Med"},{"key":"1315_CR5","doi-asserted-by":"publisher","first-page":"2000550","DOI":"10.2807\/1560-7917.ES.2020.25.14.2000550","volume":"25","author":"I Steffens","year":"2020","unstructured":"Steffens I. A hundred days into the coronavirus disease (COVID-19) pandemic. Euro Surveill. 2020;25:2000550. https:\/\/doi.org\/10.2807\/1560-7917.ES.2020.25.14.2000550.","journal-title":"Euro Surveill"},{"key":"1315_CR6","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/S0140-6736(20)30746-7","volume":"395","author":"K Leung","year":"2020","unstructured":"Leung K, Wu JT, Liu D, Leung GM. First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning: a modelling impact assessment. Lancet. 2020;395:1382\u201393. https:\/\/doi.org\/10.1016\/S0140-6736(20)30746-7.","journal-title":"Lancet."},{"key":"1315_CR7","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1016\/S2468-2667(20)30090-6","volume":"5","author":"BJ Cowling","year":"2020","unstructured":"Cowling BJ, Ali ST, Ng TWY, Tsang TK, Li JCM, Fong MW, et al. Impact assessment of non-pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study. Lancet Public Health. 2020;5:e279\u2013e288. https:\/\/doi.org\/10.1016\/S2468-2667(20)30090-6.","journal-title":"Lancet Public Health"},{"key":"1315_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jhin.2020.04.016","volume":"105","author":"LE Wee","year":"2020","unstructured":"Wee LE, Conceicao EP, Sim XYJ, Aung MK, Tan KY, Wong HM, et al. Minimizing intra-hospital transmission of COVID-19: the role of social distancing. J Hosp Infect. 2020;105:113\u20135. https:\/\/doi.org\/10.1016\/j.jhin.2020.04.016.","journal-title":"J Hosp Infect"},{"key":"1315_CR9","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","volume":"119","author":"U Chakravarthy","year":"2012","unstructured":"Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399\u2013411.","journal-title":"Ophthalmology"},{"key":"1315_CR10","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388\u201398.","journal-title":"Ophthalmology"},{"key":"1315_CR11","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.ophtha.2010.12.019","volume":"118","author":"FG Holz","year":"2011","unstructured":"Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology. 2011;118:663\u201371.","journal-title":"Ophthalmology"},{"key":"1315_CR12","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"WJ Guan","year":"2020","unstructured":"Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382:1708\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2002032.","journal-title":"N Engl J Med."},{"key":"1315_CR13","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","volume":"323","author":"Z Wu","year":"2020","unstructured":"Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239\u201342. https:\/\/doi.org\/10.1001\/jama.2020.2648.","journal-title":"JAMA."},{"key":"1315_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/IAE.0000000000001496","volume":"38","author":"D Barthelmes","year":"2018","unstructured":"Barthelmes D, Nguyen V, Daien V, Campain A, Walton R, Guymer R, et al. Two year outcomes of \u201ctreat and extend\u201d intravitreal therapy using aflibercept preferentially for neovascular age-related macular degeneration. Retina. 2018;38:20\u201328.","journal-title":"Retina"},{"key":"1315_CR15","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ophtha.2018.11.025","volume":"126","author":"RH Guymer","year":"2019","unstructured":"Guymer RH, Markey CM, McAllister IL, Gillies MC, Hunyor AP, Arnold JJ, et al. Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID study 24-month results. Ophthalmology. 2019;126:723\u201334.","journal-title":"Ophthalmology"},{"key":"1315_CR16","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","volume":"37","author":"M Ohji","year":"2020","unstructured":"Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y, et al. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial. Adv Ther. 2020;37:1173\u201387.","journal-title":"Adv Ther"},{"key":"1315_CR17","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/IAE.0b013e318296b271","volume":"34","author":"MC Gillies","year":"2014","unstructured":"Gillies MC, Walton R, Liong J, Arnold JJ, McAllister I, Morlet N, et al. Efficient capture of high-quality data on outcomes of treatment for macular diseases: the Fight Retinal Blindness! Project. Retina. 2014;34:188\u201395.","journal-title":"Retina"},{"key":"1315_CR18","unstructured":"Foundation for Statistical Computing. R: a language and environment for statistical computing [computer program]. Vienna, Austria: R Foundation for Statistical Computing; 2017."},{"key":"1315_CR19","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s12325-017-0483-1","volume":"34","author":"RL Johnston","year":"2017","unstructured":"Johnston RL, Carius HJ, Skelly A, Ferreira A, Milnes F, Mitchell P. A retrospective study of ranibizumab treatment regimens for neovascular age-related macular degeneration (nAMD) in Australia and the United Kingdom. Adv Ther. 2017;34:703\u201312.","journal-title":"Adv Ther"},{"key":"1315_CR20","doi-asserted-by":"publisher","first-page":"e911","DOI":"10.1111\/aos.13751","volume":"96","author":"P Lanzetta","year":"2018","unstructured":"Lanzetta P, Cruess AF, Cohen SY, Slakter JS, Katz T, Sowade O, et al. Predictors of visual outcomes in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapy: post hoc analysis of the VIEW studies. Acta Ophthalmol. 2018;96:e911\u20138.","journal-title":"Acta Ophthalmol"},{"key":"1315_CR21","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ophtha.2018.11.036","volume":"126","author":"CL Nguyen","year":"2019","unstructured":"Nguyen CL, Gillies MC, Nguyen V, Daien V, Cohn A, Banerjee G, et al. Characterization of poor visual outcomes of neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor agents. Ophthalmology. 2019;126:735\u201342.","journal-title":"Ophthalmology"},{"key":"1315_CR22","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.oret.2020.03.017","volume":"4","author":"KY Chong Teo","year":"2020","unstructured":"Chong Teo KY, Saxena N, Gan A, Wong TY, Gillies MC, Chakravarthy U, et al. Detrimental Effect of Delayed Re-treatment of Active Disease on Outcomes in Neovascular Age-Related Macular Degeneration: The RAMPS Study. Ophthalmol Retina. 2020;4:871\u201380. https:\/\/doi.org\/10.1016\/j.oret.2020.03.017.","journal-title":"Ophthalmol Retina."},{"key":"1315_CR23","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1097\/IAE.0b013e31827b6324","volume":"33","author":"SY Cohen","year":"2013","unstructured":"Cohen SY, Mimoun G, Oubraham H, Zourdani A, Malbrel C, Quere S, et al. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study. Retina. 2013;33:474\u201381.","journal-title":"Retina"},{"key":"1315_CR24","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s00417-017-3890-8","volume":"256","author":"B Eldem","year":"2018","unstructured":"Eldem B, Lai TYY, Ngah NF, Vote B, Yu HG, Fabre A, et al. An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER study. Graefes Arch Clin Exp Ophthalmol. 2018;256:963\u201373.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1315_CR25","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1136\/bjophthalmol-2013-303232","volume":"97","author":"FG Holz","year":"2013","unstructured":"Holz FG, Bandello F, Gillies M, Mitchell P, Osborne A, Sheidow T, et al. Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme. Br J Ophthalmol. 2013;97:1161\u20137.","journal-title":"Br J Ophthalmol"},{"key":"1315_CR26","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","volume":"392","author":"P Mitchell","year":"2018","unstructured":"Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet. 2018;392:1147\u201359.","journal-title":"Lancet"},{"key":"1315_CR27","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ajo.2019.03.001","volume":"204","author":"A Invernizzi","year":"2019","unstructured":"Invernizzi A, Nguyen V, Teo K, Barthelmes D, Fung A, Vincent A, et al. Five-year real-world outcomes of occult and classic choroidal neovascularization: data from the Fight Retinal Blindness! Project. Am J Ophthalmol. 2019;204:105\u201312.","journal-title":"Am J Ophthalmol"},{"key":"1315_CR28","first-page":"1849","volume":"7","author":"JM Rakic","year":"2013","unstructured":"Rakic JM, Leys A, Brie H, Denhaerynck K, Pacheco C, Vancayzeele S, et al. Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study. Clin Ophthalmol. 2013;7:1849\u201358.","journal-title":"Clin Ophthalmol"},{"key":"1315_CR29","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.ophtha.2017.10.010","volume":"125","author":"P Rao","year":"2018","unstructured":"Rao P, Lum F, Wood K, Salman C, Burugapalli B, Hall R, et al. Real-world vision in age-related macular degeneration patients treated with single anti-VEGF drug type for 1 year in the IRIS Registry. Ophthalmology. 2018;125:522\u20138.","journal-title":"Ophthalmology"},{"key":"1315_CR30","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1016\/j.ophtha.2016.07.012","volume":"123","author":"RW Essex","year":"2016","unstructured":"Essex RW, Nguyen V, Walton R, Arnold JJ, McAllister IL, Guymer RH, et al. Treatment patterns and visual outcomes during the maintenance phase of treat-and-extend therapy for age-related macular degeneration. Ophthalmology. 2016;123:2393\u2013400.","journal-title":"Ophthalmology"},{"key":"1315_CR31","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.oret.2019.05.013","volume":"3","author":"V Nguyen","year":"2019","unstructured":"Nguyen V, Vaze A, Fraser-Bell S, Arnold J, Essex RW, Barthelmes D, et al. Outcomes of suspending VEGF inhibitors for neovascular age-related macular degeneration when lesions have been inactive for 3 months. Opthamol Retina. 2019;3:623\u20138.","journal-title":"Opthamol Retina"},{"key":"1315_CR32","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41433-020-0956-3","volume":"34","author":"S Chandra","year":"2020","unstructured":"Chandra S, Flanagan D, Hingorani M, Lotery A, Sivaprasad S. COVID19 and ophthalmology: a brief summary of the literature. Eye (Lond). 2020;34:1200\u20132. https:\/\/doi.org\/10.1038\/s41433-020-0956-3.","journal-title":"Eye (Lond)"},{"key":"1315_CR33","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/s41433-020-0960-7","volume":"34","author":"KYC Teo","year":"2020","unstructured":"Teo KYC, Chan RVP, Cheung CMG. Keeping our eyecare providers and patients safe during the COVID-19 pandemic. Eye (Lond). 2020;34:1161\u20132. https:\/\/doi.org\/10.1038\/s41433-020-0960-7.","journal-title":"Eye (Lond)"},{"key":"1315_CR34","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00417-020-04703-x","volume":"258","author":"JF Korobelnik","year":"2020","unstructured":"Korobelnik JF, Loewenstein A, Eldem B, Joussen AM, Koh A, Lambrou GN, et al. Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic. Graefes Arch Clin Exp Ophthalmol. 2020;258:1149\u201356. https:\/\/doi.org\/10.1007\/s00417-020-04703-x.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1315_CR35","unstructured":"Royal College of Ophthalmologists. Medical retinal management plans during COVID-19. Royal College of Ophthalmologists. https:\/\/www.rcophth.ac.uk\/wp-content\/uploads\/2020\/03\/Medical-Retinal-Management-Plan-during-COVID-19-UPDATED-300320-1-3.pdf. Accessed 30 Mar 2020."},{"key":"1315_CR36","unstructured":"Maberley DMZ, Chaudhary V, Kertes P, Hooper P, Whelan J, Kherani A, et al. Additional considerations to help manage the anti-VEGF injection burden during the COVID-19 pandemic. Association of Canadian University Professors of Ophthalmology. https:\/\/www.cosprc.ca\/resource\/additional-considerations-to-help-manage-the-anti-vegf-injection-burden-during-the-covid-19-pandemic\/. Accessed 4 Apr 2020."},{"key":"1315_CR37","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ajo.2007.10.004","volume":"145","author":"CD Regillo","year":"2008","unstructured":"Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145:239\u201348.","journal-title":"Am J Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-020-01315-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-020-01315-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-020-01315-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T10:04:03Z","timestamp":1632132243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-020-01315-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,25]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1315"],"URL":"https:\/\/doi.org\/10.1038\/s41433-020-01315-x","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,25]]},"assertion":[{"value":"8 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MCG and DB are inventors of the software used to collect the data for this analysis, the copyright is owned by the University of Sydney.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}